FDA clears Heartvue’s cardiac image evaluation software
September 3, 2026
Heartvue.Proton is designed to streamline cardiovascular MRI evaluation.
Heartvue.Proton is designed to streamline cardiovascular MRI evaluation.
A new Northwestern Medicine study has uncovered a biological mechanism that may explain why a subset of tumors unexpectedly grows at an accelerated rate after being treated with certain immunotherapies, according to findings published in the journal Cancer Discovery.
Mayo Clinic researchers tested an approach that uses artificial intelligence (AI) to help people without previous ultrasound experience capture heart images and identify patients who may have a common and serious heart valve condition.
A review by University of Manchester scientists says sophisticated lab-grown tumors could help fast-track the search for new cancer treatments while reducing reliance on animal testing.
Molecules called reactive oxygen species, which include so-called “free radicals,” have long been viewed as damaging byproducts of our body’s metabolism—a reason antioxidant supplements have been considered a potential way to reduce cancer risk.
New FDA clearances expand Hamamatsu’s FDA-cleared NanoZoomer portfolio with compact benchtop and high-throughput digital pathology solutions.
Beginning October 1, 2026, hospitals using Bayesian’s continuous sepsis monitor can receive additional Medicare reimbursement for eligible inpatient cases, the first reimbursement pathway of its kind for presuspicion sepsis monitoring.
CPETWise automates and standardises CPET workflow, transforming complex physiological data into streamlined processes.
The autonomous triage system’s European market authorisation comes as AI becomes increasingly embedded into the cancer screening paradigm.
Stryker (NYSE: SYK) has announced the first clinical use of SportsSuite Vision using the mixed-reality Apple Vision Pro.